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The LGI1 gene was suggested to function as tumor suppressor for its ability to reduce malignant features of glioblastoma cells. In
support to this proposal were the ﬁndings that overexpression of LGI1 in neuroblastoma cells inhibited proliferation and induced
apoptosis. In this study we performed stable LGI1 expression in HeLa cells to examine whether the noxious eﬀect of LGI1 might be
extendedtocancercellsofdiverseorigin.HeLacellclonesstablyexpressingLGI1exhibitedasigniﬁcantimpairmentofproliferation
and a consistent increase of cell death when compared with control cells lacking expression of LGI1. Expression of LGI1 increased
the activity of apoptosis eﬀectors caspase-3/7; furthermore it downregulated the antiapoptotic BCL2 gene and upregulated the
proapoptotic BAX gene expression, suggesting that the cause of HeLa cells death might be an increased susceptibility to apoptosis
induced by LGI1. The results suggested that LGI1 is capable to restrain growth and survival of adenocarcinoma cells such as HeLa.
Copyright © 2009 N. Gabellini and V. Masola. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The leucine-rich, glioma inactivated 1 (LGI1) gene was
identiﬁed at the brake point of a reciprocal chromosome
translocation t(10;19)(q24;q13) in the glioblastoma cell
line T98G [1]. LGI1 protein includes domains presum-
ably involved in protein-protein interaction such as the
leucine-rich repeats ﬂanked by cysteine rich regions and
the seven-bladed beta-propeller domain [2–4]. LGI1 gene
is predominantly expressed in brain, and it is associated
withautosomaldominantlateraltemporalepilepsy(ADLTE)
[5, 6]. Although the speciﬁc function of LGI1 remains
to be deﬁned, it was suggested to form complexes with
Kv1.1 potassium channels, essential regulators of synaptic
transmission in brain and also to be a ligand of the trans-
membrane receptor ADAM22, a protein highly expressed in
brain whose function is still uncertain [7, 8].
The loss of LGI1 expression in most high-grade gliomas
supported the function of tumor suppressor gene [1]. In
agreement with this hypothesis the reexpression of LGI1 in
glioma cells, lacking endogenous LGI1, impaired cell growth
and migration capacity [9]. These phenotypic changes
were linked with the downregulation of matrix metallopro-
teinase (MMP) genes by LGI1-mediated inhibition of the
ERK/MAPKpathway[10].AroleofLGI1inthedevelopment
ofmalignantbraintumorswassubstantiatedbythediscovery
of somatic missense mutations in LGI1 gene associated with
high- and low-grade gliomas [11]. The ability of LGI1 to
suppressor growth of neuroblastoma cells was suggested
by the results of LGI1 overexpression, which was shown
to impair proliferation and to induce apoptosis through
the inhibition of the PI3K/AKT pathway [12, 13]. Further
support to the tumor suppressor function of LGI1 was
provided by a comprehensive study on malignant esophageal
tumors (Barrett’s-related adenocarcinomas) showing that
expression of LGI1 was consistently downregulated [14].
The aim of this study was to establish whether LGI1
was capable to suppress growth of cancer cells diﬀerent
from glioblastoma and neuroblastoma. For this purpose
we performed stable expression of LGI1 in HeLa cell,
which is derived from a human cervical adenocarcinoma
and expresses the human papillomavirus proteins E6/E7
(HPV-18) [15]. Essentially these viral proteins sustain cell
proliferation and survival through the inactivation of tumor2 International Journal of Cell Biology
suppressors p53 and pRB, which are implicated in cell cycle
arrest and induction of apoptosis [16, 17]. For these features
conferring remarkably vigorous growth, HeLa cells appeared
to be especially appropriate to test the eﬀects of LGI1.
The results showed that expression of LGI1 inhibited
the rate of HeLa cell proliferation and increased cellular
death.FurthermoreLGI1alteredexpressionofkeyregulators
of apoptosis such as the antiapoptotic B-cell lymphoma
2 gene (BCL2) and of the proapoptotic B-cell lymphoma
2-associated X protein gene (BAX) [18] .T h el e t h a le ﬀect
produced by LGI1 expression in HeLa cells suggests that the
proposed role of tumor suppressor might be extended to
adenocarcinoma-derived cells.
2.MaterialsandMethods
2.1. Cell Culture and Transfection. HeLa cells (ATCC Num-
ber: CCL-2) were cultured in Dulbecco’s Modiﬁed Eagle
medium (DMEM, low glucose) with 10% heat inactivated
Fetal Calf Serum (FCS). For transfection cells (1.5 × 106)
were seeded on 10cm diameter plastic dishes. Transfection
with plasmid pcLGI1 including the human LGI1 cDNA
(2075bp) or with empty vector pcDNA3 (10μg/mL each;
Invitrogen, Groningen, The Netherlands) was performed
by the DNA Ca2+-phosphate coprecipitation. Cells were
cultured for 48 hours after transfection; then they were
replated at low density. Stable transfected cell clones were
selected by neomycin G418 (1–0.5mM).
2.2. RT-PCR. Total RNA was isolated from subconﬂuent
cells by the GeneElute Mammalian total RNA Kit (Sigma
Chemical Co., St Louis, MO, USA). The cDNA synthesis was
performed by the reverse transcriptase ImProm-II starting
from random primer examer (Promega, Madison, WI USA).
For quantiﬁcation of LGI1 mRNA, a cDNA segment of
(236bp) was ampliﬁed with primers: 5 -TGTAAACTG-
AAATGGCTAGTGGAA, and 5 -AGTAAAAGGCTGAGC-
GATGACTAC. Ampliﬁcation of a BCL2 segment (258bp)
was carried out with primers: 5 -GGTCATGTGTGTGGA-
GAGCGT, and 5 -ACTTCACTTGTGGCTCAGATAGGC.
A BAX fragment (539bp) was ampliﬁed with primers:
5 -CCAGCTCTGAGCAGATCATG and 5 -TCAGCCCAT-
CTTCTTCCAGA. A portion of the Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, 909bp) was ampliﬁed
using primers: 5 -GACCCCTTCATTGACCTCAACTACA
and 5 -GGTCTTACTCCTTGGAGGCCATGT (Clontech,
Palo Alto, CA USA). For the semiquantitative RT-PCR
analysis diﬀerent number of PCR cycles (<25) and serial
cDNA dilutions were employed to establish conditions of
linear ampliﬁcation. The PCR products were separated by
agarosegelelectrophoresis;thenthenetintensityofethidium
bromide stained bands was determined using the Kodak 1D
Image Analysis Software.
2.3. Western Blot. Total cellular proteins (50μg) were sepa-
rated on 10%-polyacrylamide gels. The following antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA USA) were
used to probe blots: antibody C-19 directed to the C-
terminal peptide of LGI1 (60KDa), aﬃnity puriﬁed poly-
clonal antibody (BAX Δ21) against BAX protein (23KDa),
and monoclonal antibodies to Bcl-2 and GAPDH proteins
(28KDa and 36KDa, respectively . The immunoreactions
were revealed by the ECL reagent (Pharmacia Amersham
Biotech, Little Chalfont, UK) and quantiﬁed by the Kodak
1D Image Analysis Software by evaluating the net intensity
of the bands.
2.4. Proliferation Test. An ELISA immunoassay based on
BrDU incorporation was employed to measure cell pro-
liferation according to the instruction procedures (Roches
Diagnostic, Germany). Cells were plated in quadruplicate on
96 well cluster plates (100cells/mm2) and cultured for 24
hours. Absorbance at (450–690nm) was measured using a
plate reader.
2.5. Cell Death. To determine the fraction of dead cells,
the lactate dehydrogenase (LDH) released in the medium
and that present in intact cells was measured using the
CytoTox Non-Radioactive Cytotoxicity Assay (Promega,
Madison, WI USA). Cells were plated on 96-well plates
(100cells/mm2) and cultured for 24 hours. One half of
the culture medium was transferred to a fresh well to
determine LDH spontaneously released by dead cells. Lyses
of intact cells were performed in the other half of culture
medium. Then the conversion of tetrazolium salt (INT) into
the red formazan product by LDH activity was measured
(Absorbance 490nm). The fraction of dead cells was calcu-
lated as follows: % cytotoxicity = [Spontaneously released
LDH ×2 ×100]/Total LDH.
2.6. Caspase-3/7. The Apo-ONE Homogeneous caspase-3/7
assay (Promega) was employed to determine caspase-3/7
activity. Cells were seeded on 96-well plates (100cells/mm2),
and the caspase-3/7 substrate Z-DEVD-R110 was added 24
hours later. The reaction was carried on for 6 hours, and
the measurement of ﬂuorescence was then performed by
a plate spectroﬂuorimeter (485nm excitation wavelength,
530nm emission wavelength). LDH assays were performed
on replicated cell samples to determine the number of living
cells, which was used to normalize caspase activity.
2.7. Statistical Analysis. Experimental data were expressed as
the mean ± SD. To determine the signiﬁcance of variations,
valueswereanalyzedbyStudent’st-test;levelsofP<. 05were
considered to be signiﬁcant.
3. Results and Discussion
Stable transfection of HeLa cells with LGI1 cDNA was
performed to establish whether expression of LGI1 might
aﬀect cell viability. The level of LGI1 expression was eval-
uated in three cell clones designated He-LGI1-1, He-LGI1-
2, and He-LGI1-3, respectively (Figure 1). The results of the
quantiﬁcation of LGI1 mRNA was quite in agreement with
the estimated values of LGI1 protein (Table 1). AlthoughInternational Journal of Cell Biology 3
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Figure 1: RT-PCR analysis and Western blot. The expression of
LGI1, BCL2, BAX, and GAPDH was evaluated in HeLa cell clones
expressing LGI1 (HeLGI-1, -2, -3) and control cells transfected with
empty vector (He-pcDNA3). The results of RT-PCR analysis are
shown in panel (a), those of Western blotting in panel (b).
LGI1 protein was detected in whole cells sample, the
possibility that it might be secreted as it occurred in 293T
cells [19] cannot be excluded, since it might be bound to the
cell surface.
The endogenous expression of LGI1 in nontransfected
HeLa cells and in cell clones stably transfected with empty
vector was undetectable by RT-PCR and Western blotting
(seeHe-pcDNA3;Figure 1andTable 1).TheabsenceofLGI1
expression in human uterine tumors and in normal uterine
tissue is supported by the analysis of Expressed Sequence
Tags (ESTs) reported by UniGene and is in agreement with
lack of LGI1 expression in mouse uterus [20].
The BrDU incorporation procedure was employed to
evaluate the inﬂuence of LGI1 expression on the rate of HeLa
cell proliferation. All cell clones expressing LGI1 exhibited
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Figure 2: Cell proliferation. Cell clones He-LGI1-1, -2, and
-3 and control cells He-pcDNA3 were analyzed by the BrDU
incorporation procedure. Proliferation of HeLa cells expressing
LGI1 was signiﬁcantly lower than that of control cells (n = 6–11;
P<. 0001).
a lower proliferation rate in comparison with control cells
transfected with empty vector (Figure 2), which were similar
to nontransfected HeLa cells (not shown). With He-LGI1-1
cell clone, in which LGI1 expression is very little, decrease
of cell proliferation was on average 30%. With He-LGI1-
2 cells, expressing the highest LGI1 levels the decrease was
80%, whereas it was 70% with HeLGI1-3 cells, showing
intermediate levels of LGI1 expression (Figure 2). The results
showedthattheinhibitoryeﬀectofLGI1oncellproliferation
was proportional with the levels of LGI1 expression.
To establish whether expression of LGI1 also might aﬀect
survival of HeLa cells we measured the amount of LDH
spontaneously released in the medium as a consequence of
cell death. The fraction of dead cells was signiﬁcantly greater
in cell clones expressing LGI1 in comparison with control
cells (Figure 3). In particular, the percentage of He-LGI1-1
deadcellswasonaverage7%,slightlybutsigniﬁcantlygreater
than that of He-pcDNA3 cells, which was 5%. The lethal
eﬀect was much greater with He-LGI1-2 and He-LGI1-3,
whose fractions of dead cells were on average 26% and 21%,
respectively.Thedeclineofcellsurvivalwasclearlycorrelated
with the levels of LGI1 expression, likewise inhibition of cell
proliferation. Since signiﬁcant eﬀects were obtained with cell
clone HeLGI1-1 expressing very low levels of LGI1, it can
be suggested that the impairment of cell proliferation and
survival was a consequence of the proper LGI1 activity rather
than the outcome of artiﬁcial overexpression. Furthermore,
these eﬀects on cells of epithelial origin exclude the require-
ment of interactions with proteins speciﬁcally expressed in4 International Journal of Cell Biology
Table 1: Quantiﬁcation of LGI1, BCL2, and BAX expression in HeLa cell clones. The net intensity values were determined by densitometry
andnormalizedtotheaverageGAPDHcontentofeachcellsample.ThevaluesofBCL2andBAXareshownasratiowithHe-pcDNA3values.
The expression of BCL2 and BAX in all cell clones expressing LGI1 signiﬁcantly diﬀers from that of pc-DNA3 cells (n = 3 −6; P<. 01).
Cell clones LGI1 BCL2 BAX
mRNA Protein mRNA Protein mRNA Protein
H e - p c D N A 3 001111
He-LGI1-1 0.11 ±0.02 0.30 ±0.01 0.67 ±0.07 0.72 ±0.09 1.50 ±0.14 3.39 ± 0.10
He-LGI1-2 2.61 ±0.14 1.48 ±0.26 0.52 ±0.02 0.56 ±0.09 1.75 ±0.07 4.67 ± 0.59
He-LGI1-3 1.89 ±0.35 1.22 ±0.07 0.70 ±0.03 0.86 ±0.06 1.31 ±0.02 2.27 ± 0.13
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Figure 3: Cell Death. The percentage of cell death was measured on
cell clones He-LGI1-1, -2, and -3 and He-pcDNA3 by LDH assays.
Cell death was signiﬁcantly enhanced in He-LGI1-1 in comparison
with control cells (n = 22–26; P = .02), and it was much greater
with cell clones He-LGI1-2 and He-LGI1-3 (n = 10–26; P<. 001,
22E-18 ).
brain for the ability of LGI1 to contrast cell growth and
survival.
To gain information on the process of HeLa cell death
caused by the expression of LGI1 we measured the activity of
the apoptosis eﬀectors caspase-3 and -7 in the experimental
conditions employed to monitor cell death (Figure 4). The
relative ﬂuorescence emitted by the speciﬁc caspase-3/7
substrate upon cleavage was particularly enhanced with He-
LGI1-2 (7.4-fold) and He-LGI-3 cells (4.2-fold), whereas a
modest increase was measured with He-LGI1-1 (Figure 3).
The results supported the possibility that expression of LGI1
might trigger apoptosis of HeLa cells.
To substantiate the induction of apoptosis of HeLa cell
expressing LGI1 we measured the level of the antiapoptotic
BCL2 and of the proapoptotic BAX gene expression, since
the relative proportion of these proteins plays a central role
i nt h ec o n t r o lo fc e l ls u r v i v a l[ 18]. A signiﬁcant decrease
of BCL2 mRNA and protein was measured in cell clones
expressing LGI1 in comparison with control cells, whereas
the expression of BAX was consistently increased (Figure 1;
Table 1). In particular, the upregulation of BAX expression
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Figure 4: Caspase-3/7 activity. The relative ﬂuorescence (RFLU)
emitted upon cleavage of the speciﬁc by caspase-3/7 substrate Z-
DEVD-R110 was divided to the number of living cells to normalize
basal activity. The activity was greater in He-LGI1 cells than in He-
pcDNA3 (n = 6–8; P<. 03).
was proportional with the levels of LGI1, with a maximum
increase of 4.6-fold of BAX protein in He-LGI1-2 (Table 1).
The results showed that the antiapoptotic BCL2 gene was
downregulated and that of its opponent proapoptotic BAX
was upregulated as a consequence of LGI1 expression.
A decreased ratio of BCL2/BAX favors the release of
apoptogenic molecules from mitochondria, which activate
the intrinsic pathway of apoptosis in various cancer cells,
including HeLa [21–26]. Thus LGI1 might increase the sus-
ceptibility of HeLa cells to spontaneous apoptosis, similarly
to what occurred in neurobalstoma cells [12].
Apparently LGI1 was capable to counteract eﬃciently
the oncogenicity of HPV, speciﬁcally of the viral protein
E6, which prevents apoptosis by stimulating the ubiquitin-
mediated degradation of p53, a transcriptional regulator
capable to enhance the expression of BAX and to repress
that of BCL2 [16, 27–29]. Thus the balance of theseInternational Journal of Cell Biology 5
apoptoticfactorsimposedbyE6tosustaincellsurvivalmight
be destabilized by LGI1 in favor of apoptosis. Although
the mechanism of cell death induced by LGI1 has not
been completely elucidated, it seems possible that LGI1
might interfere with central survival pathways such as
the PI3K/AKT, as it occurred in neuroblastoma cells [13],
because the prosurvival eﬀects of this pathway includes
transcriptional regulation of BCL2 and BAX genes [30, 31].
In conclusion, this study supports the possibility that
LGI1 might act as tumor suppressor of adenocarcinoma-
derived cells, in line with the downregulation of LGI1
reported in Barrett’s-related adenocarcinomas and with
previous studies on glioblastoma and neuroblastoma cells
[9–14].
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